We use cookies on our website. Some are necessary for the operation of the website. You can also allow cookies for statistical purposes. You can adjust the data protection settings or agree to all cookies directly.
Data Protection Declaration
Imprint
Improving phenotypic testing of AMR by development of rapid and sensitive screening assays for emerging resistances and setting missing ECOFFs (Epidemiologic cutoff values) (IMPART)
Project
Project code: BfR-BIOS-08-1342
Contract period: 01.01.2018
- 31.12.2019
Purpose of research: Applied research
IMPART includes four topics related to the development and harmonization of phenotypic methods for detection of antimicrobial resistance: (1) selective isolation and detection of colistin-resistant Enterobacteriaceae, (2) selective isolation and detection of carbapenemase-producing Enterobacteriaceae, (3) development of a standardized disk diffusion method for susceptibility testing of Clostridium difficile, (4) setting ECOFFs for specific veterinary pathogen/antibiotic combinations. IMPART will result in a harmonized sensitive method to detect colistin-resistant (carrying mcr) (WP1) and carbapenemase-producing Enterobacteriaceae (WP2) in caecal samples from animals and in food. Setting a standardised and optimised methodology is essential for accurate monitoring of the current prevalence and spread of bacteria carrying these emerging resistance genes in humans, animals and food. . Additionally, as C. difficile infection treatment failure are frequently reported and susceptibility test methodology problematic, IMPART aim to provide a suitable and cost-effective method for antimicrobial resistance surveillance of the zoonotic pathogen C. difficile. A disk diffusion method will be developed and standardized for a broad range of antimicrobials. The generated distributions of inhibition zone diameters will support future work on setting epidemiological cut-off values (ECOFFs) (WP4). Furthermore, AMR surveillance in veterinary pathogens has generated very few standardized data compared to the human pathogens. IMPART will actively collect MIC-values of the most prioritized pathogens and antimicrobials for veterinary medicine. After consensual priority setting, the generated data will allow the setting of ECOFFs for veterinary pathogens. Those ECOFFs will highly improve the harmonization of resistance monitoring of animal pathogens and support the process for defining animal species-specific clinical breakpoints for veterinary antimicrobials (WP3). Ultimately, IMPART will contribute to a more effective and prudent use of antimicrobials in animals. Finally, IMPART means Improving Phenotypic AMR testing, the last “T” could have meant “together”. IMPART aims at upgrading the skills and knowledge of the 13 partners from nine countries to a common harmonized level that will allow our teams to contribute to a better comprehension of the AMR hazard. Then, knowledge and experience would be shared inside IMPART and disseminated outside IMPART using efficient and innovative tools (WP5).
Section overview
Subjects
- Biotechnology
- Genetic Resources
